Back

Assessment of long-term damage and cardiovascular risk in juvenile systemic lupus erythematosus compared to juvenile dermatomyositis in adulthood

Li, J.; Ali, I.; Mailoo, T.; Doddi, S.; Raj, N.; Palmer, E.; Ciurtin, C.

2026-04-04 rheumatology
10.64898/2026.03.30.26349504 medRxiv
Show abstract

Objectives: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are systemic autoimmune rheumatic diseases (RMDs) with childhood-onset associated with increased risk of damage accumulation and cardiovascular disease (CVD) over the life course. Methods: Damage associated with JSLE and JDM has been assessed using validated outcome measures in a longitudinal single-centre cohort study with long-term follow-up, involving data collected both retrospectively and prospectively. Descriptive statistics, sensitivity and regression analyses have been used to evaluate predictors of damage and CVD-risk. Results: We assessed comparatively a JSLE cohort (n=76), with a mean age of 24.3 +/- 4.2 years and a JDM cohort (n=79) with a mean 20.1 +/-5.0 years (p<0.001), with matched duration of follow-up (10.0 +/- 4.2 vs. 11.0 +/- 5.1, respectively, p=0.68). Traditional CVD-risk factors, including hypertension (p=0.02), dyslipidaemia (p=0.0005), and higher total cholesterol (p=0.01) and LDL-cholesterol (p=0.02) levels at the last assessment were higher in JSLE vs. JDM. Over the disease course, 39 (51.3%) AYA with JSLE vs. 47 (59.4%) AYA with JDM accumulated damage (p=0.307), which was independently predicted by the body mass index in both cohorts (p=0.038 and p=0.026, respectively). The PDAY score was the only tool able to stratify AYA based on CVD-risk (median = 5 (4-13) points in JSLE vs. 0 (0-3) points in JDM, p=0.0001), as all the adult CVD-risk scores were very low in both cohorts. Conclusions: This is the first comparative evaluation of JSLE vs. JDM in adulthood, which highlighted increased damage burden and CVD-risk in JSLE that warrants further investigation.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Rheumatology
21 papers in training set
Top 0.1%
25.6%
2
RMD Open
13 papers in training set
Top 0.1%
17.5%
3
Annals of the Rheumatic Diseases
32 papers in training set
Top 0.1%
10.1%
50% of probability mass above
4
Arthritis & Rheumatology
33 papers in training set
Top 0.1%
8.4%
5
Frontiers in Immunology
586 papers in training set
Top 1%
6.4%
6
PLOS ONE
4510 papers in training set
Top 32%
4.9%
7
Frontiers in Medicine
113 papers in training set
Top 1%
3.7%
8
The Lancet Rheumatology
11 papers in training set
Top 0.1%
3.6%
9
Journal of Internal Medicine
12 papers in training set
Top 0.2%
1.8%
10
Arthritis Research & Therapy
15 papers in training set
Top 0.2%
1.7%
11
Scientific Reports
3102 papers in training set
Top 64%
1.3%
12
Frontiers in Endocrinology
53 papers in training set
Top 2%
1.2%
13
Journal of Allergy and Clinical Immunology
25 papers in training set
Top 0.6%
0.9%
14
Clinical Immunology
21 papers in training set
Top 0.5%
0.9%
15
Biomedicines
66 papers in training set
Top 2%
0.9%
16
Journal of Personalized Medicine
28 papers in training set
Top 0.9%
0.9%
17
Genome Medicine
154 papers in training set
Top 8%
0.7%
18
International Journal of Molecular Sciences
453 papers in training set
Top 16%
0.7%
19
Clinical Infectious Diseases
231 papers in training set
Top 5%
0.7%
20
Stem Cell Research & Therapy
30 papers in training set
Top 0.9%
0.7%
21
European Journal of Neuroscience
168 papers in training set
Top 2%
0.6%